For Cyborg Trading Systems (CTS) – a financial technology services company that serves an international network of banks, brokers and professional traders – keeping ahead of competition is absolutely essential. Battling huge enterprises like Thomson Reuters, Bloomberg and Goldman Sachs would seem an almost impossible task for a Canadian SME. With the cost of infrastructure, technology and global employees rising by the second, Lukez is always looking for any and all opportunities to innovate.
The research led to a 78% reduction in CT image noise which facilitates a corresponding decrease in the patient radiation exposure required for high quality CT images, saving patients from the potentially harmful effects of X-ray dose radiation. Below is an exclusive interview with Mr. Hashemi, who won the Mitacs Award for Novelty in Application, as presented by the Honourable Gail Shea, Minister of National Revenue at the 2nd Annual Mitacs Awards Reception, held November 28th in Ottawa.
Because of this research, BC Children’s Hospital can how examine all new cases of pediatric brain tumors throughout the entirety of Western Canada with precision and accuracy – thus reducing the (often excessive) intensity of treatment for children with cancer while still effectively treating the disease. Below is an exclusive interview with Ms.
It was Dr. Janice Singer, an IRAP-Industry Technology Advisor, who awarded Rafael the 1st prize in the poster competition and saw the great potential in Rafael’s and Larus' mutual interest in wireless sensors and robot networks.
For the last year and a half, Side Effects Software had been developing a web-based marketplace for highly-customizable 3D content. Similar to Apple’s App Store or Android’s Market, the company’s Orbolt™ Smart Asset Store is an application marketplace where digital artists can purchase smart 3D assets. Entering the e-commerce marketplace for the first time meant the company faced a number of unique challenges. They turned to Yeleiny through Mitacs-Accelerate for web performance expertise.
By 2020, it is estimated that diabetes will cost the Canadian healthcare system $16.9 billion a year. In response, Calgary-based Orpyx Medical Technologies is developing a product that is garnering the attention of the diabetes technology community. The SurroSense Rx is a pressure sensitive insole that relays plantar pressure information to a wristwatch, notifying the user when damage is being done to their feet so that behavior can be modified to avoid complications.
Over the course of his Accelerate internship Zaifman, a postdoctoral fellow at the Chemistry department of the University of British Columbia, partnered with AlCana, a Vancouver biotechnology company developing lipid nanoparticles, which show great potential as a new means for the targeted delivery of therapeutics.
One of the most talked-about biomedical breakthroughs of 2010, this new development offers hope to sufferers of blood and immunological diseases, such as leukemias, who are often unable to find a suitable donor.
“Ideally, under further development, we hope to be able to grow mature blood cells for patients from their own skin, lessening the likelihood of rejection,” Eva said.